Pen & Prosperity
Website: https://penandprosperity.vgcet.com
Volume 2 :: Issue 4 :: December 2025 :: e-ISSN- 3048-9555 :: DOI Link : https://doi.org/10.70798/PP/020400016

The Role of Immune Dysregulation in Emotional and Affective Disturbances

Pratiksha Goswami

SACT -1, Netaji Mahavidyalaya

Email ID: 2019.pratikshagoswami@gmail.com

Abstract:

This article presents a multidisciplinary investigation into the role of immune dysregulation in emotional and affective disturbances. Drawing upon psychoneuroimmunology, neurobiology, endocrinology, and clinical psychiatry, it examines the mechanisms through which immune activation influences brain function and emotional regulation. The review highlights pathways of immune–brain communication, including cytokine signaling, neurotransmitter alterations, and hypothalamic–pituitary–adrenal (HPA) axis activation. Evidence linking chronic inflammation to major depressive disorder, anxiety disorders, post-traumatic stress disorder, and affective symptoms in autoimmune diseases is critically examined. Developmental factors such as early-life adversity and maternal immune activation, along with lifestyle influences including diet, sleep, exercise, and social relationships, are explored as modulators of immune-emotional interactions. Clinical implications are discussed, emphasizing anti-inflammatory interventions, lifestyle modification, and biomarker-guided personalized treatment strategies. The findings underscore the importance of an integrated biopsychosocial framework that conceptualizes emotional disturbances as systemic conditions involving immune, neural, and endocrine processes.

A R T I C L E I N F O

Article history:
Received: 10 November 2025
Received in revised form
20 November 2025
Accepted 29 November 2025

Citation: Goswami. P., (2025) "The Role of Immune Dysregulation in Emotional and Affective Disturbances", *Pen and Prosperity*, Vol. 2, Issue. 4, December 2025.

Keywords: *Psychoneuroimmunology; Inflammation; Depression; Cytokines; Immune–Brain Interaction.*

Introduction:

For much of modern medical history, the immune system and the emotional life of the individual were treated as separate domains. Immunology concerned itself with pathogens, inflammation, and defense mechanisms, while psychology and psychiatry focused on mood, cognition, and behavior. However, advances in neuroscience, endocrinology, and psychoneuroimmunology have fundamentally transformed this fragmented perspective. It is now widely recognized that the immune system and the central nervous system engage in constant bidirectional communication, influencing each other through complex biochemical and neural pathways. Emotional and affective disturbances—including depression, anxiety disorders, bipolar disorder, and stress-related conditions—are increasingly understood not only as psychological phenomena but also as disorders with significant immunological components.

Immune dysregulation refers to an imbalance or maladaptive functioning of the immune system, including chronic low-grade inflammation, excessive production of pro-inflammatory cytokines, impaired immune

surveillance, or autoimmune activity. Such dysregulation can alter neural function, neurotransmitter metabolism, and hormonal balance, thereby influencing mood and emotional regulation. Conversely, chronic emotional distress and stress-related conditions can disrupt immune functioning, creating a self-perpetuating cycle of psychological and physiological disturbance.

Objectives:

This article presents a multidisciplinary investigation into the role of immune dysregulation in emotional and affective disturbances. Drawing from psychoneuroimmunology, neurobiology, endocrinology, and clinical psychiatry, it examines mechanisms of immune-brain communication, inflammatory pathways in mood disorders, developmental influences, and implications for prevention and intervention.

Theoretical Foundations: Psychoneuroimmunology and the Integrated Model

Psychoneuroimmunology (PNI) emerged in the late twentieth century as a field dedicated to understanding the interactions among psychological processes, the nervous system, and the immune system (Ader, 2001). Early experimental work demonstrated that immune responses could be conditioned and that stress altered immune parameters, challenging the notion that immunity operates independently of psychological states (Ader & Cohen, 1975; Cohen et al., 1991). These findings laid the groundwork for a biopsychosocial model in which emotional experiences are embedded within physiological systems (Engel, 1977).

Within this integrated framework, the immune system communicates with the brain through multiple channels (Dantzer et al., 2008). Cytokines—small signaling proteins released by immune cells—play a central role in this communication (Maier & Watkins, 1998). Pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) can cross the blood–brain barrier or signal the brain via afferent vagal pathways (Banks, 2005; Tracey, 2002). Once in the central nervous system, these molecules influence neurotransmitter systems, neuroendocrine activity, and neural plasticity (Miller et al., 2009).

This conceptual shift reframes emotional disturbances not solely as "chemical imbalances" within the brain but as systemic conditions involving immune, endocrine, and neural interactions (Raison & Miller, 2011). Depression, for example, is increasingly conceptualized as a disorder that, in some individuals, involves chronic low-grade inflammation and altered immune signaling (Miller & Raison, 2016). Thus, emotional dysregulation may reflect disruptions in immune-brain homeostasis (Dantzer et al., 2008).

Mechanisms of Immune-Brain Communication:

The immune system influences the brain through both humoral and neural routes (Maier & Watkins, 1998). Peripheral immune activation triggers the release of cytokines into the bloodstream (Dantzer et al., 2008). Although the blood–brain barrier restricts direct entry of many substances, cytokines can affect brain function through specialized transport mechanisms or by activating endothelial cells lining cerebral blood vessels (Banks, 2005). Additionally, the vagus nerve provides a rapid neural pathway through which peripheral inflammation signals the brain (Tracey, 2002).

Once inflammatory signals reach the brain, they alter neurotransmitter metabolism (Miller et al., 2009). One key mechanism involves the tryptophan–kynurenine pathway (O'Connor et al., 2009). Pro-inflammatory cytokines activate the enzyme indoleamine 2,3-dioxygenase (IDO), which shifts tryptophan metabolism away from serotonin synthesis toward kynurenine production (Schwarcz et al., 2012). Reduced availability of tryptophan for serotonin synthesis may contribute to depressive symptoms, while certain kynurenine metabolites have neurotoxic properties that affect glutamatergic neurotransmission (Haroon et al., 2012).

Inflammation also influences dopamine pathways involved in motivation and reward (Felger & Miller, 2012). Elevated cytokine levels are associated with reduced dopaminergic signaling in the basal ganglia, contributing to anhedonia—a core symptom of depression characterized by diminished pleasure or motivation (Capuron et al., 2012). Furthermore, inflammatory processes may impair neuroplasticity by reducing levels of brain-derived neurotrophic factor (BDNF), thereby affecting learning, memory, and emotional resilience (Calabrese et al., 2014).

In addition to neurotransmitter alterations, immune dysregulation activates the hypothalamic–pituitary–adrenal (HPA) axis (Raison & Miller, 2003). Pro-inflammatory cytokines stimulate corticotropin-releasing hormone (CRH) production in the hypothalamus, leading to increased cortisol secretion (Turnbull & Rivier, 1999). Chronic HPA axis activation may further disrupt immune balance, producing glucocorticoid resistance—a state in which immune cells become less responsive to cortisol's anti-inflammatory effects (Pace et al., 2007). This creates a vicious cycle in which inflammation persists despite elevated cortisol levels (Miller et al., 2009).

Inflammation and Depression:

Major depressive disorder (MDD) is one of the most extensively studied conditions in relation to immune dysregulation (Miller & Raison, 2016). Numerous studies have demonstrated elevated levels of inflammatory markers, including IL-6, TNF-α, and C-reactive protein (CRP), in individuals with depression (Dowlati et al., 2010; Howren et al., 2009). While not all depressed patients exhibit inflammatory abnormalities, a significant subgroup appears to experience "inflammatory depression," characterized by heightened immune activation (Raison & Miller, 2011).

Clinical observations support this association. Patients receiving interferon-alpha therapy for hepatitis C or certain cancers frequently develop depressive symptoms, indicating that immune activation alone can induce mood disturbances (Capuron et al., 2002). Experimental administration of endotoxin in controlled settings has been shown to produce transient depressive and anxiety-like symptoms in healthy individuals, further underscoring the causal potential of inflammatory processes (Reichenberg et al., 2001).

Inflammation-related depression often presents with specific symptom clusters, including fatigue, sleep disturbances, cognitive impairment, and reduced motivation (Haroon et al., 2012). These features align with "sickness behavior," an adaptive response during infection characterized by withdrawal, lethargy, and reduced appetite (Dantzer & Kelley, 2007). While beneficial during acute illness, chronic activation of sickness behavior pathways may contribute to persistent mood disorders (Dantzer et al., 2008).

Anxiety Disorders and Immune Dysregulation:

Although the association between inflammation and depression has been more extensively documented, a growing body of research indicates that anxiety disorders also demonstrate significant immunological correlates. Chronic anxiety and prolonged stress exposure activate both the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, resulting in increased production of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) (Miller, Chen, & Cole, 2009). Sustained stress-related arousal may alter immune cell distribution, including shifts in lymphocyte subsets and enhanced inflammatory gene expression, thereby promoting a pro-inflammatory phenotype (Segerstrom & Miller, 2004). Clinical studies have reported elevated inflammatory markers in individuals diagnosed with generalized anxiety disorder (GAD), panic disorder, and post-traumatic stress disorder (PTSD), suggesting that immune dysregulation may contribute to both the onset and maintenance of anxiety symptoms (Vogelzangs et al., 2013).

PTSD, in particular, illustrates the intricate interplay between trauma, immune activation, and emotional dysregulation. Exposure to traumatic events has been associated with long-term alterations in immune functioning, including persistent low-grade inflammation and impaired glucocorticoid receptor sensitivity (Yehuda et al., 2015). Reduced glucocorticoid sensitivity limits cortisol's anti-inflammatory effects, allowing inflammatory processes to remain chronically activated. Elevated cytokine levels may influence neural circuits involved in fear conditioning and threat detection, particularly within the amygdala and prefrontal cortex, thereby intensifying hypervigilance, sleep disturbances, and intrusive memories (Raison & Miller, 2013). These immunological alterations can reinforce symptom persistence, creating a bidirectional cycle in which psychological stress sustains immune activation, and immune activation amplifies emotional distress.

Beyond their psychological manifestations, anxiety-related immune changes may increase vulnerability to somatic diseases. Chronic sympathetic activation promotes endothelial dysfunction, oxidative stress, and inflammatory signaling, all of which contribute to the development of atherosclerosis and cardiovascular disease (Steptoe & Kivimäki, 2012). Elevated inflammatory markers in anxious individuals have been associated with increased risk of hypertension and coronary artery disease, highlighting the systemic consequences of prolonged emotional dysregulation. Thus, anxiety disorders exemplify the interconnected nature of emotional and physiological health.

Autoimmune Disorders and Affective Symptoms:

Autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis are frequently accompanied by depressive and anxiety symptoms at rates significantly higher than those observed in the general population (Dantzer et al., 2008). While psychosocial stressors—including chronic pain, disability, and uncertainty about disease progression—contribute to emotional distress, mounting evidence suggests that immunological mechanisms also play a direct and substantial role in affective disturbances.

Autoimmune disorders are characterized by persistent immune activation and excessive cytokine production. Pro-inflammatory mediators can influence brain function through direct and indirect pathways, altering neurotransmitter systems, neural plasticity, and neuroendocrine regulation (Miller & Raison, 2016). In multiple sclerosis, inflammatory demyelinating lesions within the central nervous system may directly disrupt neural circuits responsible for mood regulation, particularly those involving fronto-limbic connectivity (Gold et al., 2010). Similarly, in rheumatoid arthritis, elevated systemic inflammation has been associated with increased depressive symptoms independent of pain severity, suggesting that inflammatory activity itself contributes to mood alterations (Matcham et al., 2013).

In systemic lupus erythematosus, neuropsychiatric manifestations—including depression, anxiety, and cognitive impairment—are thought to result from both inflammatory cytokine activity and autoantibody-mediated effects on neural tissue (Hanly et al., 2007). These biological influences demonstrate that emotional disturbances in autoimmune conditions cannot be attributed solely to psychological reactions to chronic illness; rather, they often reflect underlying immunopathology.

Developmental and Environmental Influences:

Emerging research underscores the profound influence of developmental and environmental factors on immune regulation and emotional functioning. Early-life adversity—including childhood trauma, neglect, socioeconomic deprivation, and chronic stress—has been consistently associated with long-term alterations in immune activity. Individuals exposed to adverse childhood experiences (ACEs) frequently exhibit

elevated levels of inflammatory markers such as interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α) well into adulthood (Danese et al., 2007). These findings suggest that early stress does not merely affect psychological development but becomes biologically embedded within immune pathways. Chronic activation of stress-response systems during sensitive developmental periods may recalibrate the hypothalamic–pituitary–adrenal (HPA) axis and sympathetic nervous system, fostering a pro-inflammatory phenotype that persists across the lifespan (Miller, Chen, & Parker, 2011).

One plausible mechanism underlying these long-term effects involves epigenetic modification. Early adversity has been linked to changes in DNA methylation and histone modification patterns that regulate immune gene expression, particularly genes involved in inflammatory signaling and glucocorticoid receptor sensitivity (McGowan et al., 2009). Such epigenetic changes may diminish the body's capacity to regulate inflammatory responses effectively, thereby increasing vulnerability to depression, anxiety, and other affective disturbances later in life. This process of "biological embedding" illustrates how environmental stressors can become inscribed within immune function, shaping emotional health trajectories.

Maternal immune activation during pregnancy further exemplifies the intersection of immune processes and neurodevelopment. Prenatal exposure to elevated inflammatory cytokines—resulting from maternal infection, stress, or autoimmune conditions—has been associated with increased risk of neurodevelopmental and affective disorders in offspring, including autism spectrum disorder, schizophrenia, and mood disorders (Brown & Derkits, 2010; Estes & McAllister, 2016). Inflammatory mediators can cross the placental barrier or alter placental functioning, influencing fetal brain development. Cytokine exposure during critical periods may disrupt neuronal migration, synapse formation, and microglial activation, ultimately affecting neural connectivity and stress reactivity (Knuesel et al., 2014). These alterations may predispose individuals to heightened emotional sensitivity or dysregulated stress responses across the lifespan.

Lifestyle and environmental conditions in adulthood continue to modulate immune–emotional interactions. Obesity, poor diet (particularly diets high in processed foods and saturated fats), physical inactivity, and sleep deprivation are all associated with chronic low-grade systemic inflammation (Calder et al., 2011). Adipose tissue, especially visceral fat, acts as an endocrine organ that secretes pro-inflammatory cytokines, thereby amplifying inflammatory signaling pathways. Sleep deprivation further disrupts immune regulation, increasing circulating inflammatory markers and impairing adaptive immune responses (Irwin, 2015). These inflammatory states are, in turn, linked to greater risk of depression and anxiety, suggesting a bidirectional relationship between lifestyle behaviors and emotional well-being.

Conversely, protective lifestyle factors exert anti-inflammatory and mood-enhancing effects. Regular physical exercise has been shown to reduce systemic inflammation, improve glucocorticoid sensitivity, and stimulate the release of anti-inflammatory cytokines (Pedersen & Saltin, 2015). Balanced nutrition rich in omega-3 fatty acids, antioxidants, and fiber supports immune homeostasis and has been associated with lower rates of depressive symptoms (Lopresti, Hood, & Drummond, 2013). Adequate and restorative sleep contributes to optimal immune regulation and emotional resilience.

Social and environmental contexts further shape immune responses. Social isolation and chronic loneliness have been linked to pro-inflammatory gene expression profiles, including upregulation of genes involved in innate immune responses and downregulation of antiviral defense genes (Cole et al., 2007). This "conserved transcriptional response to adversity" reflects the evolutionary intertwining of social experience and immune function. In contrast, strong social support networks buffer stress-related immune activation and promote emotional stability, partly by attenuating HPA axis overactivation and inflammatory signaling (Uchino, 2006).

Clinical Implications and Therapeutic Approaches:

Recognition of immune contributions to emotional disturbances has important clinical implications (Miller & Raison, 2016). Anti-inflammatory agents, including nonsteroidal anti-inflammatory drugs (NSAIDs), cytokine inhibitors, and omega-3 fatty acids, have been investigated as adjunct treatments for depression (Köhler et al., 2014; Raison et al., 2013). Some studies suggest that individuals with elevated inflammatory markers may respond better to anti-inflammatory interventions (Strawbridge et al., 2015).

Lifestyle-based interventions, such as exercise and stress reduction programs, may improve mental health partly by modulating immune activity (Pedersen & Saltin, 2015; Irwin & Cole, 2011). Mindfulness meditation has been associated with reduced inflammatory gene expression and improved emotional regulation (Black & Slavich, 2016). Psychotherapy may also influence immune function indirectly by reducing stress and enhancing coping strategies (Slavich & Irwin, 2014).

Personalized medicine approaches that identify inflammatory biomarkers could enable targeted treatment strategies (Raison & Miller, 2011). Not all individuals with mood disorders exhibit immune dysregulation; therefore, biomarker-guided interventions may enhance treatment efficacy and reduce unnecessary medication exposure (Felger & Lotrich, 2013).

Conclusion:

Immune dysregulation plays a significant role in the development and maintenance of emotional and affective disturbances. Through intricate pathways linking cytokines, neurotransmitters, neuroendocrine systems, and neural circuits, immune activation influences mood, motivation, cognition, and behavior. Depression, anxiety disorders, PTSD, and affective symptoms in autoimmune conditions illustrate the profound interdependence of immune and emotional systems.

Understanding these interactions fosters a holistic approach to mental health that integrates biological, psychological, and social dimensions. Future research must continue to clarify the mechanisms underlying immune-emotional interactions and identify biomarkers that guide personalized interventions. Ultimately, recognizing the immune system as a central contributor to emotional regulation enriches both scientific knowledge and clinical practice, advancing a more comprehensive and compassionate model of mental health care.

Reference

- Ader, R. (2001). Psychoneuroimmunology (3rd ed.). Academic Press.
- Ader, R., & Cohen, N. (1975). Behaviorally conditioned immunosuppression. *Psychosomatic Medicine, 37*(4), 333–340.
- Banks, W. A. (2005). Blood–brain barrier transport of cytokines: A mechanism for neuropathology. *Current Pharmaceutical Design, 11*(8), 973–984.
- Black, D. S., & Slavich, G. M. (2016). Mindfulness meditation and the immune system: A systematic review of randomized controlled trials. *Annals of the New York Academy of Sciences, 1373*(1), 13–24.
- Brown, A. S., & Derkits, E. J. (2010). Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. *American Journal of Psychiatry, 167*(3), 261–280.

- Calabrese, F., Rossetti, A. C., Racagni, G., & Riva, M. A. (2014). Brain-derived neurotrophic factor: A bridge between inflammation and neuroplasticity. *Frontiers in Cellular Neuroscience, 8*, 430.
- Calder, P. C., Ahluwalia, N., Brouns, F., et al. (2011). Dietary factors and low-grade inflammation in relation to overweight and obesity. *British Journal of Nutrition, 106*(S3), S5–S78.
- Capuron, L., Ravaud, A., & Dantzer, R. (2002). Early depressive symptoms in cancer patients receiving interleukin-2 and/or interferon-alpha-2b therapy. *Journal of Clinical Oncology, 20*(9), 2143–2151.
- Capuron, L., Pagnoni, G., Drake, D. F., & Miller, A. H. (2012). Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. *Archives of General Psychiatry, 69*(10), 1044–1053.
- Cohen, S., Tyrrell, D. A., & Smith, A. P. (1991). Psychological stress and susceptibility to the common cold. *New England Journal of Medicine, 325*(9), 606–612.
- Cole, S. W., Hawkley, L. C., Arevalo, J. M. G., et al. (2007). Social regulation of gene expression in human leukocytes. *Genome Biology, 8*(9), R189.
- Danese, A., Pariante, C. M., Caspi, A., Taylor, A., & Poulton, R. (2007). Childhood maltreatment predicts adult inflammation in a life-course study. *Proceedings of the National Academy of Sciences, 104*(4), 1319–1324.
- Dantzer, R., & Kelley, K. W. (2007). Twenty years of research on cytokine-induced sickness behavior. *Brain, Behavior, and Immunity, 21*(2), 153–160.
- Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression. *Nature Reviews Neuroscience, 9*(1), 46–56.
- Dowlati, Y., Herrmann, N., Swardfager, W., et al. (2010). A meta-analysis of cytokines in major depression. *Biological Psychiatry, 67*(5), 446–457.
- Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. *Science, 196*(4286), 129–136.
- Estes, M. L., & McAllister, A. K. (2016). Maternal immune activation and neuropsychiatric disorders. *Science, 353*(6301), 772–777.
- Felger, J. C., & Lotrich, F. E. (2013). Inflammatory cytokines in depression. *Neuropsychopharmacology, 38*(1), 52–63.
- Felger, J. C., & Miller, A. H. (2012). Cytokine effects on the basal ganglia and dopamine function. *Biological Psychiatry, 72*(1), 4–13.
- Gold, S. M., Irwin, M. R., & Mohr, D. C. (2010). Depression in multiple sclerosis. *The Lancet Neurology, 5*(2), 157–168.
- Hanly, J. G., Urowitz, M. B., Su, L., et al. (2007). Prospective analysis of neuropsychiatric events in systemic lupus erythematosus. *Annals of the Rheumatic Diseases, 66*(6), 801–807.
- Haroon, E., Raison, C. L., & Miller, A. H. (2012). Psychoneuroimmunology meets neuropsychopharmacology. *Neuropsychopharmacology, 37*(1), 137–162.

- Howren, M. B., Lamkin, D. M., & Suls, J. (2009). Associations of depression with C-reactive protein, IL-1, and IL-6. *Psychosomatic Medicine, 71*(2), 171–186.
- Irwin, M. R. (2015). Why sleep is important for health. *Annual Review of Psychology, 66*, 143–172.
- Irwin, M. R., & Cole, S. W. (2011). Reciprocal regulation of the neural and innate immune systems. *Nature Reviews Immunology, 11*(9), 625–632.
- Knuesel, I., Chicha, L., Britschgi, M., et al. (2014). Maternal immune activation and abnormal brain development. *Brain, Behavior, and Immunity, 38*, 1–14.
- Köhler, O., Benros, M. E., Nordentoft, M., et al. (2014). Effect of anti-inflammatory treatment on depression. *JAMA Psychiatry, 71*(12), 1381–1391.
- Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2013). A review of lifestyle factors in depression. *Journal of Affective Disorders, 148*(1), 12–27.
- Maier, S. F., & Watkins, L. R. (1998). Cytokines for psychologists. *Psychological Bulletin, 124*(1), 83–107.
- Matcham, F., Rayner, L., Steer, S., & Hotopf, M. (2013). The prevalence of depression in rheumatoid arthritis. *Rheumatology, 52*(12), 2136–2148.
- McGowan, P. O., Sasaki, A., D'Alessio, A. C., et al. (2009). Epigenetic regulation of the glucocorticoid receptor in human brain. *Nature Neuroscience, 12*(3), 342–348.
- Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression. *Nature Reviews Immunology, 16*(1), 22–34.
- Miller, A. H., Maletic, V., & Raison, C. L. (2009). Inflammation and its discontents. *Biological Psychiatry, 65*(9), 732–741.
- Miller, G. E., Chen, E., & Cole, S. W. (2009). Health psychology: Developing biologically plausible models. *Annual Review of Psychology, 60*, 501–524.
- Miller, G. E., Chen, E., & Parker, K. J. (2011). Psychological stress in childhood and susceptibility to chronic diseases. *Psychological Bulletin, 137*(6), 959–997.
- O'Connor, J. C., Lawson, M. A., André, C., et al. (2009). Lipopolysaccharide-induced depressive-like behavior. *Journal of Neuroscience, 29*(13), 4200–4209.
- Pace, T. W. W., Hu, F., & Miller, A. H. (2007). Cytokine effects on glucocorticoid receptor function. *Biological Psychiatry, 62*(9), 1004–1013.
- Pedersen, B. K., & Saltin, B. (2015). Exercise as medicine. *Scandinavian Journal of Medicine & Science in Sports, 25*(S3), 1–72.
- Raison, C. L., & Miller, A. H. (2003). When not enough is too much. *American Journal of Psychiatry, 160*(9), 1554–1565.
- Raison, C. L., & Miller, A. H. (2011). Is depression an inflammatory disorder? *Current Psychiatry Reports, 13*(6), 467–475.

- Raison, C. L., & Miller, A. H. (2013). The evolutionary significance of depression. *Molecular Psychiatry, 18*(1), 15–37.
- Reichenberg, A., Yirmiya, R., Schuld, A., et al. (2001). Cytokine-associated emotional and cognitive disturbances. *Archives of General Psychiatry, 58*(5), 445–452.
- Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H. Q. (2012). Kynurenines in the mammalian brain. *Nature Reviews Neuroscience, 13*(7), 465–477.
- Segerstrom, S. C., & Miller, G. E. (2004). Psychological stress and the human immune system. *Psychological Bulletin, 130*(4), 601–630.
- Slavich, G. M., & Irwin, M. R. (2014). From stress to inflammation and major depressive disorder. *Psychological Bulletin, 140*(3), 774–815.
- Steptoe, A., & Kivimäki, M. (2012). Stress and cardiovascular disease. *Nature Reviews Cardiology, 9*(6), 360–370.
- Strawbridge, R., Arnone, D., Danese, A., et al. (2015). Inflammation and clinical response to treatment in depression. *European Neuropsychopharmacology, 25*(10), 1532–1543.
- Tracey, K. J. (2002). The inflammatory reflex. *Nature, 420*(6917), 853–859.
- Turnbull, A. V., & Rivier, C. L. (1999). Regulation of the HPA axis by cytokines. *Physiological Reviews, 79*(1), 1–71.
- Uchino, B. N. (2006). Social support and health. *Journal of Behavioral Medicine, 29*(4), 377–387.
- Vogelzangs, N., Beekman, A. T. F., de Jonge, P., & Penninx, B. W. J. H. (2013). Anxiety disorders and inflammation. *Psychoneuroendocrinology, 38*(6), 797–805.
- Yehuda, R., Daskalakis, N. P., Lehrner, A., et al. (2015). Influences of trauma on epigenetic regulation. *Biological Psychiatry, 77*(2), 107–115.